REG - Biofrontera AG - Director/PDMR Shareholding <Origin Href="QuoteRef">B8FGn.DE</Origin>
RNS Number : 8654QBiofrontera AG04 September 2014Biofrontera AG
("Biofrontera" or the "Company")
Director Dealing
Biofrontera AG (AIM:B8F), the European biopharmaceutical company, announces that on 4 September 2014 Thomas Schaffer, the Chief Financial Officer of the Company, purchased 2,000 ordinary shares of no par value in the capital of the Company ("Ordinary Shares") at a price of EUR 2.320 per Ordinary Share. Subsequent to this transaction Mr Schaffer has a beneficial interest in 10,088 Ordinary Shares representing 0.045% of the issued ordinary share capital of the Company.
For further information, please contact:
Biofrontera AG
Prof. Hermann Lbbert, Chief Executive Officer
Thomas Schaffer , Chief Financial Officer
Tel:+ 49 (0) 214 - 87632 - 22
finnCap (Nomad and Broker)
Geoff Nash / Christopher Raggett (Corporate Finance)
Tel: 020 7220 0500
Steven Norcross(Corporate Broking)
Investor Relations
Seton Services
Toni Vallen
Tel: 020 7603 6797
Financial PR
Gable Communications
John Bick
Tel: 020 7193 7463
This information is provided by RNSThe company news service from the London Stock ExchangeENDRDSLIMTTMBIMBLI
Recent news on Biofrontera AG
See all newsRCS - Maruho Deutschland - Extraordinary General Meeting on 7 April 2022
AnnouncementREG - AIM Biofrontera AG - Cancellation - Biofrontera AG <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Private Placement <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Phase III studies update <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Excellent results in Ameluz BCC clinical study <Origin Href="QuoteRef">B8FGn.DE</Origin>
Announcement